Because of this, there is a significant risk associated with buying Celldex stock -- just as there would be with any other clinical-stage biotech …
Biotech Stocks
Inc. CLDX. Shares have lost about 4.4% in that time frame, …
Earnings
Celldex Therapeutics closed at $3.26 a share on Thursday. The stock traded between $3.22 and $3.30 on …
Research
CLDX) during the fourth quarter, Holdings Channel reports. The firm purchased 91,158 shares of the biopharmaceutical company’s stock, valued at approximately $325,000. Other large investors also recently …
BNS7d
Stake
One stock that might be an intriguing choice for investors right now is Celldex Therapeutics, Inc. CLDX. This is because this security in the Medical-Biomedical and Genetics space is seeing solid earnings estimate …
NASDAQ4mon
NASDAQ
Inc. (CLDX) — a company with enormous catalysts that could send it doubling in 2016 — has flown under the radar. Since 2013, there has not been a more volatile biotech stock than CLDX. Celldex shares soared from …
Stock
Celldex Therapeutics Inc New (NASDAQ ... Rhenman & Partners Asset …
Bristol-Myers Squibb
Termination of the CDX-1135 study has dealt a major blow, and resulted in a drop in price of Celldex stock. Even with CDX-1135 out of the way, the stock is undervalued considering the fundamentals of Celldex's other two …
Seeking Alpha
Celldex Therapeutics Inc. (CLDX) agreed to acquire Kolltan Pharmaceuticals Inc., a New Haven, Connecticut-based clinical-stage company that makes cancer drugs, for $62.5 million in stock. Celldex could make …
Deal